🇸🇬

Singapore

Health Sciences Authority (HSA) · Asia-Pacific

Updated 1 week agohigh confidence
Export PDF
Lead approval timeline
180–270 days
180–365 days · Abridged Evaluation Route
Application fee
SGD 70,000
SGD 70,000 (Abridged NDA-1)
English submissions
Accepted
English
eCTD
Accepted
See dossier notes
Local representative
Required
RP also required
Reliance pathway
Available
7 reference agencies
Last verified 4/18/2026 · by GlobalReg Editorial

Executive summary

Singapore is regulated by the Health Sciences Authority (HSA), a statutory board of the Ministry of Health, established in 2001 by the Health Sciences Authority Act. HSA operates under the Health Products Act 2007 and the Medicines Act 1975 and regulates therapeutic products, medical devices, IVDs, cosmetics, complementary medicines, cell/tissue/gene therapies, blood products, and tobacco. Singapore is one of the most reliance-friendly markets globally. HSA was a founding member of the ACCESS Consortium (with TGA, Health Canada, Swissmedic, MHRA — work-sharing on new drug evaluations) and operates four routes calibrated to the level of foreign approval: Full Evaluation, Abridged, Verification, and Post-Approval. The Verification route accepts approval by 1 reference agency and is the fastest at 60–120 days. Singapore is a PIC/S member, ICH regulatory member, and recognises ICH-CTD/eCTD. Despite a market of only ~5.9M people, Singapore is a strategic regional hub for pharma — many companies use Singapore approval as the entry point for ASEAN. The Agency for Care Effectiveness (ACE) is the HTA body that recommends Standard Drug List (SDL) and Medication Assistance Fund (MAF) listings.

Regulatory authority
HSA
Operating language
English
English submissions
Accepted
Submission languages
English
CTD format
Accepted
eCTD format
Accepted

About the authority

HSA is organised into the Health Products Regulation Group (HPRG — therapeutic products, medical devices, complementary medicines, cosmetics), Blood Services Group, and Applied Sciences Group (forensic science). Within HPRG, the Therapeutic Products Branch handles drug registration and the Audit and Licensing Division handles GMP/GDP licensing. HSA operates the PRISM electronic submission portal.

International affiliations

PIC/SICH (regulatory member)ACCESS ConsortiumASEAN PPWGICMRAWHO
Visit official website

Reliance & recognition

Singapore operates one of the world's most mature reliance frameworks. Three explicit reliance routes (Abridged, Verification, ACCESS) plus reliance for GMP via PIC/S. Choice of route is calibrated by number/identity of foreign approvals and how identical the Singapore product is to the foreign-approved version.

FDAEMA (centralised)MHRAHealth CanadaTGASwissmedicPMDA